Crestor Cost in Vermont 2026: Rosuvastatin Prices, Medicaid Coverage, and Savings Options

What Does Crestor Actually Cost in Vermont Right Now?

The brand-name Crestor list price sits near $290 per month in 2026. Very few Vermont patients pay that figure. Generic rosuvastatin, available at virtually every Vermont retail pharmacy, averages approximately $15 per month on a cash-pay basis, and GoodRx-style discount cards can push that lower.

Brand vs. Generic: The Price Gap

AstraZeneca's Crestor lost patent exclusivity in 2016. Since then, multiple generic manufacturers have entered the market, collapsing cash prices. A 30-tablet supply of generic rosuvastatin 10 mg can be purchased for $10 to $18 at major Vermont chains including Hannaford Pharmacy, Kinney Drugs, and CVS as of mid-2025 pricing data.

The FDA maintains a searchable database of approved generic rosuvastatin products [1]. Switching from brand to generic does not require a new prescription in Vermont under the state's generic substitution law; your pharmacist substitutes automatically unless the prescriber writes "dispense as written."

Compounded Rosuvastatin: A $0 Option for Some Patients

Licensed 503A compounding pharmacies in Vermont may prepare patient-specific rosuvastatin formulations. Compounded rosuvastatin is not FDA-approved as a finished product, but 503A compounding is governed by federal law under the Drug Quality and Security Act and overseen at the state level by the Vermont Board of Pharmacy [2]. When bundled into a telehealth membership or subscription model, the effective patient cost can drop to $0 per month.

Compounding is appropriate only when a commercially available product does not meet a specific patient need, such as an alternative dose strength or a dye-free formulation. Patients should confirm that their 503A pharmacy holds an active Vermont permit before dispensing.

GoodRx and Discount Cards

Discount programs like GoodRx, RxSaver, and NeedyMeds are not insurance. They are negotiated pricing agreements between pharmacy benefit intermediaries and retail pharmacies. In Vermont, these cards regularly reduce generic rosuvastatin to under $12 per month at participating locations. The savings apply at the point of sale and do not count toward an insurance deductible.

Vermont Medicaid Coverage for Rosuvastatin

Vermont Medicaid (Green Mountain Care) covers rosuvastatin for hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD) prevention, but the drug requires prior authorization (PA) on the preferred drug list [3]. A prescriber must document that the patient meets clinical criteria before the state will reimburse.

How Prior Authorization Works in Vermont

PA criteria for statins under Vermont Medicaid typically require:

• A confirmed diagnosis of hyperlipidemia (ICD-10 E78.x), familial hypercholesterolemia, or documented ASCVD risk.
• Documentation of LDL-C above guideline thresholds or a 10-year ASCVD risk score at or above 7.5%, consistent with the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease [4].
• Evidence that a formulary-preferred lower-cost statin (usually simvastatin or pravastatin) was trialed or is contraindicated.

Approval typically takes two to five business days. Urgent PA requests can be expedited within 24 hours under Vermont Medicaid rules.

What Vermont Medicaid Pays After PA Approval

Once approved, Vermont Medicaid members generally pay a nominal copay of $1 to $3 per prescription for generic rosuvastatin. Brand-name Crestor is subject to a higher cost-sharing tier and is rarely approved over generic unless a documented clinical reason exists.

Vermont also participates in the federal 340B Drug Pricing Program, which allows qualifying health centers to purchase rosuvastatin at significantly reduced prices and pass savings to low-income patients [5]. Federally Qualified Health Centers (FQHCs) across Vermont, including Community Health Centers of Burlington and the Health Center in Plainfield, participate in 340B.

Does Insurance Cover Crestor in Vermont?

Most commercial insurance plans operating in Vermont cover generic rosuvastatin. Brand Crestor coverage depends heavily on plan formulary tier.

Commercial Plans on Vermont's Health Connect Exchange

Vermont uses a state-based exchange (Vermont Health Connect) for individual and small-group plans. All Qualified Health Plans (QHPs) sold on the exchange must cover generic statins as preventive medications with zero cost-sharing for adults aged 21 to 75 who meet USPSTF criteria, per the ACA preventive services mandate [6].

The USPSTF recommends prescribing a statin for primary prevention of CVD events in adults aged 40 to 75 who have one or more CVD risk factors and an estimated 10-year CVD event risk of 10% or greater [7]. Vermont QHP enrollees who meet these USPSTF criteria pay $0 for generic rosuvastatin at in-network pharmacies.

Employer-Sponsored Plans

Employer-sponsored plans follow federal ERISA rules and may have their own formularies. Generic rosuvastatin is classified as a Tier 1 or Tier 2 drug on most commercial formularies. Tier 1 copays in Vermont employer plans typically range from $0 to $15 per month. Brand Crestor usually lands on Tier 3 or Tier 4, with copays of $40 to $100 per month, making the generic the practical choice for most employees.

Medicare Part D in Vermont

Medicare Part D covers rosuvastatin across all Vermont plan formularies. Under the Inflation Reduction Act, the Part D out-of-pocket cap was set at $2,000 annually beginning in 2025, which limits total statin spending for Medicare beneficiaries [8]. Most Part D plans place generic rosuvastatin on Tier 1 with a $0 to $5 monthly copay.

The Clinical Case for Rosuvastatin: Why Providers Prescribe It

Rosuvastatin is an HMG-CoA reductase inhibitor. It reduces hepatic cholesterol synthesis, upregulates LDL receptors, and lowers LDL-C by 45% to 63% depending on dose [9]. The FDA approved rosuvastatin (Crestor) in August 2003 for multiple indications including primary hyperlipidemia, mixed dyslipidemia, and ASCVD risk reduction [10].

The JUPITER Trial

The JUPITER trial (N=17,802) is the foundational evidence base for rosuvastatin in primary prevention. Published in the New England Journal of Medicine in 2008, JUPITER enrolled patients with LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP) at or above 2.0 mg/L [11]. Rosuvastatin 20 mg daily reduced major cardiovascular events by 44% compared with placebo (hazard ratio 0.56; 95% CI, 0.46 to 0.69; P<0.001). The trial was stopped early at a median follow-up of 1.9 years because the benefit was so clear.

The JUPITER investigators concluded: "Rosuvastatin significantly reduced the incidence of major cardiovascular events" in this intermediate-risk population, a finding that directly shaped subsequent ACC/AHA guideline recommendations for statin use in primary prevention [11].

Dose Strengths and FDA-Approved Uses

Rosuvastatin is available as 5 mg, 10 mg, 20 mg, and 40 mg oral tablets taken once daily, at any time of day, with or without food [10]. FDA-approved indications include:

• Primary hyperlipidemia and mixed dyslipidemia (adults)
• Primary prevention of CVD in adults without clinically evident coronary heart disease
• Homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients aged 7 and older
• Heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older
• Hypertriglyceridemia
• Primary dysbetalipoproteinemia

The 40 mg dose is the highest approved. The FDA advises against starting patients on 40 mg unless they have already tolerated 20 mg without significant adverse effects [10].

Safety Profile and Muscle Risk

Statin-associated myopathy is the most discussed adverse effect. The incidence of rhabdomyolysis with rosuvastatin in clinical practice is estimated at approximately 0.1 per 10,000 patient-years, consistent with other high-intensity statins [12]. Risk increases with concomitant use of cyclosporine, gemfibrozil, niacin at doses above 1 g/day, or certain antiretrovirals. The 2022 ACC Expert Consensus on Statin Safety recommends checking a baseline CK in patients with a prior history of statin-associated muscle symptoms before initiating therapy [13].

Rosuvastatin is renally cleared, so dose reduction to 5 mg daily is recommended in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) [10].

Telehealth Prescribing of Rosuvastatin in Vermont

Vermont permits telehealth prescribing of rosuvastatin. A licensed Vermont provider may conduct a synchronous audio-visual visit, assess cardiovascular risk using validated tools such as the Pooled Cohort Equations, and issue a prescription for rosuvastatin without an in-person visit [14].

What a Telehealth Visit Looks Like

A standard telehealth statin initiation visit at a Vermont-licensed platform involves:

1. Patient completes a digital intake form including personal and family cardiovascular history, current medications, and recent lab values.
2. Provider reviews a recent lipid panel (within 12 months preferred) and calculates 10-year ASCVD risk.
3. Provider discusses shared decision-making per the 2019 ACC/AHA guideline, which recommends a clinician-patient risk discussion before initiating statin therapy in primary prevention patients [4].
4. If appropriate, an e-prescription for generic rosuvastatin is sent to the patient's preferred Vermont pharmacy or a mail-order pharmacy.

Baseline labs required before starting therapy typically include a fasting lipid panel, liver function tests, and a fasting glucose or HbA1c, given that statins carry a small but real risk of new-onset diabetes (approximately 0.1 additional diabetes case per 1,000 patient-years of statin use, as estimated in a Lancet meta-analysis of 13 statin trials) [15].

Vermont Telehealth Law and Prescribing Standards

Vermont's telemedicine statute (8 V.S.A. § 4100k) requires that telehealth services meet the same standard of care as in-person services. Controlled substances cannot be prescribed via telehealth without a prior in-person relationship under the Ryan Haight Act, but rosuvastatin is not a controlled substance, so this restriction does not apply [16].

The AstraZeneca Savings Card and Patient Assistance Programs

AstraZeneca offers a co-pay savings card for brand-name Crestor. Eligible commercially insured patients may pay as little as $3 per month for brand Crestor using the AstraZeneca savings card [17]. Vermont residents qualify if they have commercial insurance; the program explicitly excludes patients covered by federal programs including Medicare Part D, Medicaid, or TRICARE.

Vermont-Specific Cost Decision Framework

The table below organizes Vermont patients by payer type and the likely lowest-cost path to rosuvastatin in 2026.

| Patient Type | Likely Lowest-Cost Path | Estimated Monthly Cost | |---|---|---| | Uninsured, low income | Vermont Medicaid enrollment or 340B FQHC | $0 to $3 | | Uninsured, higher income | GoodRx discount + generic at Hannaford/Kinney | $10 to $15 | | Commercial insurance, generic preferred | Tier 1 in-network copay | $0 to $15 | | Commercial insurance, brand preferred | AstraZeneca savings card + Tier 3 brand | $3 to $40 | | Medicare Part D | Tier 1 Part D plan copay | $0 to $5 | | Vermont Medicaid (post-PA) | State formulary generic copay | $1 to $3 | | Telehealth membership model | Compounded rosuvastatin via 503A pharmacy | $0 |

AstraZeneca's patient assistance program (AZ&Me) provides brand Crestor at no cost to uninsured or underinsured patients who meet income thresholds, generally at or below 400% of the federal poverty level [17]. Applications are processed through AstraZeneca directly or through a prescriber's office.

How Vermont Compares to National Average Rosuvastatin Prices

The national average retail price for a 30-day supply of generic rosuvastatin 10 mg in 2026 is approximately $18 to $22 without insurance, according to pricing aggregators. Vermont's average of approximately $15 per month sits modestly below the national average, partly because Vermont's pharmacy field includes several regional chains with aggressive generic pricing.

A 2021 JAMA study examining statin out-of-pocket costs found that among commercially insured U.S. Adults, 27% paid more than $20 per month for statins despite generic availability, primarily because of high-deductible plan structures [18]. Vermont's state-run exchange and relatively high Medicaid enrollment rate (approximately 24% of the population as of 2023 data from Kaiser Family Foundation) may keep effective patient costs lower than in states with fewer subsidized coverage options.

The CDC reports that approximately 93 million U.S. Adults aged 20 and older have total cholesterol above 200 mg/dL, and only about 55% of those eligible for statin therapy under current guidelines are actually receiving it [19]. Cost is consistently cited as a primary barrier to adherence. Vermont's competitive generic pricing environment and Medicaid coverage reduce that barrier compared with many other states.

Statin adherence matters clinically. A meta-analysis of 19 randomized controlled trials found that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C produced a 22% reduction in major cardiovascular events over five years [20]. Patients who discontinue rosuvastatin because of cost sacrifice that LDL reduction and the associated cardiovascular protection.

What to Do if You Cannot Afford Rosuvastatin in Vermont

Patients facing cost barriers to rosuvastatin in Vermont have several concrete next steps:

Step 1: Confirm Generic Dispensing

Ask your pharmacist specifically whether the generic version of rosuvastatin is being dispensed. If the brand is on file, request the generic. This single step reduces monthly cost from up to $290 to approximately $10 to $15 without changing the active ingredient, dose, or clinical effect [1].

Step 2: Apply a Discount Card

Download GoodRx, RxSaver, or NeedyMeds before arriving at the pharmacy. Present the card at the point of sale. These are free to use. The NeedyMeds drug discount card, in particular, is accessible to uninsured patients at no membership fee [21].

Step 3: Check Medicaid Eligibility

Vermont Medicaid has relatively broad income eligibility. Adults earning up to 138% of the federal poverty level (approximately $20,700 for a single individual in 2025) qualify for Green Mountain Care. Apply through Vermont Health Connect at healthconnect.vermont.gov [3].

Step 4: Ask About 340B Pricing

If you receive care at a community health center, rural health clinic, or FQHC in Vermont, ask the front desk whether the facility participates in 340B. Patients seen at 340B-eligible sites may receive rosuvastatin at sharply reduced prices regardless of insurance status [5].

Step 5: Contact AZ&Me

If brand Crestor is medically necessary for you and you are uninsured or underinsured, contact AstraZeneca's AZ&Me program directly. Income-qualifying patients receive brand Crestor at $0 per month [17].

Is Compounded Rosuvastatin Legal in Vermont?

Yes. Licensed 503A compounding pharmacies in Vermont may legally prepare individualized rosuvastatin formulations for specific patients under a valid prescription [2]. The Vermont Board of Pharmacy regulates these pharmacies and requires compliance with USP <795> standards for non-sterile compounding.

Compounded rosuvastatin is not bioequivalent-tested against the brand or generic finished product because the FDA does not evaluate compounded preparations the same way it evaluates new drug applications [10]. Patients using compounded rosuvastatin should have LDL-C monitored at 6 to 12 weeks after initiation to confirm therapeutic response, consistent with the ACC/AHA monitoring recommendation [4].

503B outsourcing facilities, which produce larger batches for hospitals and clinics, are not permitted to compound rosuvastatin for individual patients without a prescription. Only 503A pharmacies operating under state pharmacy board oversight may fill individual patient prescriptions for compounded rosuvastatin in Vermont.